NAD+ is a fundamental co-enzyme involved in cellular energy and metabolic function. As interest in healthy ageing grows, delivery quality becomes the difference between “taking a product” and building a programme.
Think of NAD+ as part of the cell’s “energy economy”—supporting processes linked to energy production and cellular maintenance. The challenge is that many formats struggle to get intact payload where it matters.
We position LNP-NAD+ as a premium wellness technology:
Scale revenue, not your floor plan.
Move from time-and-chair bottlenecks to fast and repeatable dispensing, supporting retention
and recurring revenue models.
Some approaches can feel like a sharp rise followed by a rapid drop. LNP-enabled sustained circulation is engineered to support a more stable experience over time.
One of the key advantages of LNP-NAD⁺ lies in its ability to deliver a controlled, predictable, and sustained NAD⁺ profile, rather than the abrupt peaks and rapid declines with the traditional delivery methods such as Liposomal technology.
High-dose bolus approaches, particularly intravenous or poorly stabilised oral formats, can lead to transient supraphysiological spikes in circulating NAD⁺, followed by rapid clearance and metabolic drop-off. This “spike-and-crash” pattern may translate into short-lived benefits, variable patient experience, and inconsistent outcomes between doses and individuals.
LNP-NAD⁺ is researched to address this challenge at a pharmacokinetic level. By encapsulating NAD⁺ within advanced lipid nanoparticles, the formulation is designed to protect the active molecule, moderate its systemic release, and enhance cellular uptake efficiency. This results in a smoother exposure curve and a more reproducible experience over time, supporting steadier mitochondrial function and cellular energy availability. For patients and clinicians alike, this translates into greater consistency, improved tolerability, and more predictable outcomes, enabling LNP-NAD⁺ to be integrated into structured, repeatable protocols rather than episodic interventions.
Beyond the clinical experience, this consistency also delivers a clear operational and commercial advantage. Predictable effects support protocol standardisation, patient retention, and subscription-based or maintenance programmes, outcomes that are far harder to achieve with variable, peak-dependent therapies. In short, LNP-NAD⁺ shifts NAD⁺ supplementation from an acute, event-driven intervention to a reliable, long-term metabolic support strategy, aligned with both clinical best practice and scalable care models.
For the safe and effective delivery of active agents at the cellular level Lipid nanoparticle (LNP) represent one of the most significant advances in modern drug delivery and are widely used across the pharmaceutical and biotechnology industries. Their clinical validation in approved medicines and vaccines demonstrates not only their effectiveness, but also their safety, scalability, and regulatory acceptability. LNPs are engineered to protect sensitive active compounds from degradation, improve bioavailability, and facilitate targeted cellular uptake, capabilities that conventional delivery formats such as Liposomal delivery system often fail to achieve.
LNP-NAD⁺ is researched to address this challenge at a pharmacokinetic level. By encapsulating NAD⁺ within advanced lipid nanoparticles, the formulation is designed to protect the active molecule, moderate its systemic release, and enhance cellular uptake efficiency. This results in a smoother exposure curve and a more reproducible experience over time, supporting steadier mitochondrial function and cellular energy availability. For patients and clinicians alike, this translates into greater consistency, improved tolerability, and more predictable outcomes, enabling LNP-NAD⁺ to be integrated into structured, repeatable protocols rather than episodic interventions.
Beyond the clinical experience, this consistency also delivers a clear operational and commercial advantage. Predictable effects support protocol standardisation, patient retention, and subscription-based or maintenance programmes, outcomes that are far harder to achieve with variable, peak-dependent therapies. In short, LNP-NAD⁺ shifts NAD⁺ supplementation from an acute, event-driven intervention to a reliable, long-term metabolic support strategy, aligned with both clinical best practice and scalable care models.
One of the most compelling advantages of LNP-NAD⁺ is the level of convenience it brings to both patients and clinics. Traditional IV-based NAD⁺ therapies require scheduled appointments, prolonged chair time, clinical supervision, and significant disruption to a patient’s day. In contrast, LNP-NAD⁺ is designed to deliver many of the same intended cellular benefits for longer but without the need for infusions, cannulation, or extended in-clinic stays. This allows patients to integrate NAD⁺ support seamlessly into their routine, whether at home, at work, or while travelling, without compromising on consistency or experience.
For clinics and providers, this “take-home IV” solutions fundamentally changes service delivery. By removing chair time from the equation, practices can expand access to NAD⁺ programmes beyond the physical limits of treatment rooms and staffing schedules. Patients can be onboarded through brief consultations and supported through structured, repeatable protocols, while clinics benefit from improved efficiency, scalability, and ongoing engagement. The result is a modern, patient-centric model that combines the perceived value of IV-style therapies with the flexibility, convenience, and sustainability of at-home use, without sacrificing clinical oversight or quality standards.
